Literature DB >> 9244071

A comparative audit of prevalent, incident and interval cancers in the Avon breast screening programme.

P A Sylvester1, M N Vipond, E Kutt, J D Davies, A J Webb, J R Farndon.   

Abstract

The 4th year of the Avon breast screening programme comprises two distinct groups: those called for screening for the first time (prevalent group) and those who were initially screened 3 years earlier (incident group). The cancer detection rate, stage of disease and rate of interval cancers in these patients have been compared. For the prevalent groups of year 1 and year 4 there was no statistically significant difference in the cancer detection rate, proportion of small tumours or node positivity. For the prevalent and incident groups of year 4, there was no statistically significant difference in the cancer detection rate or proportion of small tumours. There were significantly fewer node-positive tumours in the incident group (5/45 vs 8/23; P < 0.05). Fifty-six interval cancers presented in the 3-year period between years 1 and 4 of screening; 28 (50%) after 24 months. The screening programme may result in tumours being detected at an earlier stage, but this may be offset by the high rate of interval cancers. This suggests that the time between screens may need to be reduced to 2 years.

Entities:  

Mesh:

Year:  1997        PMID: 9244071      PMCID: PMC2502835     

Source DB:  PubMed          Journal:  Ann R Coll Surg Engl        ISSN: 0035-8843            Impact factor:   1.891


  27 in total

1.  Edinburgh trial of screening for breast cancer: mortality at seven years.

Authors:  M M Roberts; F E Alexander; T J Anderson; U Chetty; P T Donnan; P Forrest; W Hepburn; A Huggins; A E Kirkpatrick; J Lamb
Journal:  Lancet       Date:  1990-02-03       Impact factor: 79.321

2.  Breast screening: time for a rethink?

Authors:  M M Roberts
Journal:  BMJ       Date:  1989-11-04

3.  Reduction of breast cancer mortality through mass screening with modern mammography. First results of the Nijmegen project, 1975-1981.

Authors:  A L Verbeek; J H Hendriks; R Holland; M Mravunac; F Sturmans; N E Day
Journal:  Lancet       Date:  1984-06-02       Impact factor: 79.321

4.  The Swedish two county trial of mammographic screening for breast cancer: recent results and calculation of benefit.

Authors:  L Tabar; G Fagerberg; S W Duffy; N E Day
Journal:  J Epidemiol Community Health       Date:  1989-06       Impact factor: 3.710

5.  Breast cancer detection: one versus two views.

Authors:  L W Bassett; D H Bunnell; R Jahanshahi; R H Gold; R D Arndt; J Linsman
Journal:  Radiology       Date:  1987-10       Impact factor: 11.105

6.  Changes in incidence of and mortality from breast cancer in England and Wales since introduction of screening. United Kingdom Association of Cancer Registries.

Authors:  M Quinn; E Allen
Journal:  BMJ       Date:  1995-11-25

7.  Analysis of interval breast carcinomas in a randomized screening trial in Stockholm.

Authors:  J Frisell; G Eklund; L Hellström; A Somell
Journal:  Breast Cancer Res Treat       Date:  1987       Impact factor: 4.872

8.  Number of projections in mammography: influence on detection of breast disease.

Authors:  I Andersson; J Hildell; A Mühlow; H Pettersson
Journal:  AJR Am J Roentgenol       Date:  1978-02       Impact factor: 3.959

9.  The occurrence of interval cancers in the Nijmegen screening programme.

Authors:  P H Peeters; A L Verbeek; J H Hendriks; R Holland; M Mravunac; G P Vooijs
Journal:  Br J Cancer       Date:  1989-06       Impact factor: 7.640

10.  What is the optimum interval between mammographic screening examinations? An analysis based on the latest results of the Swedish two-county breast cancer screening trial.

Authors:  L Tabár; G Faberberg; N E Day; L Holmberg
Journal:  Br J Cancer       Date:  1987-05       Impact factor: 7.640

View more
  1 in total

1.  Interval cancers in the Dutch breast cancer screening programme.

Authors:  J Fracheboud; H J de Koning; P M Beemsterboer; R Boer; A L Verbeek; J H Hendriks; B M van Ineveld; M J Broeders; A E de Bruyn; P J van der Maas
Journal:  Br J Cancer       Date:  1999-11       Impact factor: 7.640

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.